Skip to main content

Table 2 Two-year survival endpoints according to metabolic response at early PET-CT in different patients’ groups

From: The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy

 

N°

Early metabolic response

Loco-regional PFS

Distant PFS

Global PFS

Overal survival

Patients who underwent early PET-CT

42

R

20

84.7%

p = 0.0007

70.7%

p = 0.0007

63.6%

p = 0.0002

73.5%

p = 0.01

NR

22

21.5%

20.5%

7.4%

45.9%

Patients who underwent final PET-CT

23

R

12

100%

p = 0.007

67.9%

p = 0.03

67.9%

p = 0.02

77.8%

p = 0.06

NR

11

35.4%

30.5%

15.2%

62.3%

Patients who underwent surgery

20

R

13

100%

p = 0.04

83.3%

p = 0.01

83.3%

p = 0.04

87.5%

p = 0.16

NR

7

41.7%

42.9%

28.6%

66.7%

  1. R responder, NR non-responder, PFS progression free survival, PET-CT positron emission tomography-computed tomography